TABLE 3.
Summary of the effects of IDO and iNOS activities on L2 growtha
| Cell lineb | Production or growth with additive(s)c
|
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| None
|
IFN-γ
|
LPS
|
IFN-γ-LPS
|
IFN-γ-TNF-α-IL-1β-LPS
|
|||||||||||
| IDO | iNOS | IFU | IDO | iNOS | IFU | IDO | iNOS | IFU | IDO | iNOS | IFU | IDO | iNOS | IFU | |
| HeLa (HE) | —d | — | 8.30 ± 0.76 | 91 | — | 5.14 ± 0.33 | — | — | 8.28 ± 0.74 | 87 | — | 5.16 ± 0.31 | 88 | — | 5.22 ± 0.46 |
| HL (HE) | — | — | 7.53 ± 0.60 | 89 | — | 5.35 ± 0.35 | — | — | 7.80 ± 0.63 | 93 | — | 5.10 ± 0.40 | NDe | ND | ND |
| A549 (HE) | — | — | 7.71 ± 0.65 | 94 | — | 5.39 ± 0.40 | — | — | 7.69 ± 0.71 | 88 | — | 5.33 ± 0.29 | 87 | — | 5.41 ± 0.32 |
| RT-4 (HE) | — | — | 7.53 ± 0.71 | 92 | — | 5.59 ± 0.36 | — | — | 7.50 ± 0.60 | 89 | — | 5.21 ± 0.33 | 49 | 7 | 5.19 ± 0.29 |
| T24 (HE) | — | — | 7.96 ± 0.72 | 92 | — | 5.56 ± 0.60 | — | — | 7.80 ± 0.71 | 94 | — | 5.60 ± 0.36 | 91 | — | 5.67 ± 0.45 |
| BeWo (HE) | — | — | 7.49 ± 0.63 | — | — | 7.46 ± 0.54 | — | — | 7.51 ± 0.59 | — | — | 7.47 ± 0.55 | ND | ND | ND |
| IEC4.1 (ME) | — | — | 6.96 ± 0.59 | — | — | 5.16 ± 0.43 | — | — | 6.79 ± 0.55 | — | — | 5.32 ± 0.38 | ND | ND | ND |
| TM3 (ME) | — | — | 6.83 ± 0.55 | — | — | 5.16 ± 0.34 | — | — | 6.82 ± 0.50 | — | — | 5.26 ± 0.42 | ND | ND | ND |
| MLE-15 (ME) | — | — | 8.19 ± 0.73 | 39 | — | 7.90 ± 0.71 | — | — | 8.20 ± 0.62 | 41 | — | 7.80 ± 0.59 | ND | ND | ND |
| BM12.4 (ME) | — | 4 | 8.37 ± 0.68 | — | 17 | 6.72 ± 0.71 | — | 3 | 8.24 ± 0.71 | — | 22 | 6.45 ± 0.61 | ND | ND | ND |
| BM1.11 (ME) | — | 12 | 7.17 ± 0.64 | — | 25 | 5.37 ± 0.46 | — | 14 | 7.24 ± 0.65 | — | 29 | 5.46 ± 0.33 | ND | ND | ND |
| McCoy (MF) | — | 3 | 8.20 ± 0.81 | — | 21 | 6.18 ± 0.50 | — | 6 | 8.19 ± 0.70 | — | 25 | 6.15 ± 0.42 | ND | ND | ND |
| L929 (MF) | — | 2 | 8.11 ± 0.77 | — | 11 | 6.31 ± 0.53 | — | 2 | 7.99 ± 0.63 | — | 13 | 6.27 ± 0.57 | ND | ND | ND |
| THP-1 (HM) | — | — | 7.96 ± 0.62 | 94 | — | 5.66 ± 0.39 | — | — | 7.89 ± 0.52 | 93 | — | 5.36 ± 0.51 | ND | ND | ND |
| RAW 264 (MM) | — | 12 | 6.19 ± 0.73 | — | 88 | 4.53 ± 0.47 | — | 82 | 4.34 ± 0.33 | — | 90 | 4.25 ± 0.34 | ND | ND | ND |
| RAW NO− (MM) | — | 1 | 6.29 ± 0.71 | — | 39 | 4.76 ± 0.52 | — | 11 | 6.19 ± 0.47 | — | 47 | 4.62 ± 0.29 | ND | ND | ND |
| J774 (MM) | — | 8 | 6.23 ± 0.66 | — | 50 | 5.17 ± 0.49 | — | 31 | 6.15 ± 0.59 | — | 42 | 5.20 ± 0.38 | ND | ND | ND |
Growth was assessed by determining the number of infectious EBs recovered 48 h Postinfection. Growth data are presented as IFU (log10) and represent the means ± standard errors SE of triplicate determinations. Tryptophan and nitrite data presented are the averages of two determinations. For tryptophan the averaged 100% control values in pmol/107 cells are as follows: HeLa, 7,247; HL, 7,432; A549, 7,789; RT-4, 6,459; T24, 6,483; BeWo, 7,256; MLE15, 5,019.
HE, human epithelial line; ME, murine epithelial; MF, murine fibroblast; HM, human monocyte; MM, murine macrophage.
Cell culture additives: IFN-γ, 20 U/ml; LPS, 20 ng/ml; TNF-α, 20 ng/ml; IL-1β, 20 ng/ml.
—, no evidence of IDO or iNOS production as judged by RT-PCR, western blotting, and/or bioassay.
ND, not determined.